CBT
SAGE icon

Capital Bank & Trust’s Sage Therapeutics SAGE Stock Holding History

Capital Bank & Trust’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-26,596
Closed -$764K – 578
2020
Q1 		$764K Buy
26,596
+4,292
+19% +$249K 0.01% 192
2019
Q4 		$1.61M Buy
+22,304
New +$2.74M 0.02% 178

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital Bank & Trust's SAGE Position: Q2 2020 in Review

Capital Bank & Trust sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 26,596 shares — an estimated $764K sold.

Capital Bank & Trust first reported a position in SAGE in Q4 2019 and held it in 2 quarters. The position peaked at $1.61M in Q4 2019. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

  • Capital Bank & Trust reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Capital Bank & Trust sold 26,596 Sage Therapeutics shares in Q2 2020, an estimated $764K.
  • Capital Bank & Trust first reported a position in Sage Therapeutics in Q4 2019 and held it in 2 quarters.
  • Capital Bank & Trust's Sage Therapeutics position peaked at $1.61M in Q4 2019.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.